Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates

Core Insights - Qiagen reported quarterly earnings of $0.55 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, and showing an increase from $0.47 per share a year ago, representing a 10% earnings surprise [1] - The company achieved revenues of $483.46 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.18% and increasing from $458.8 million year-over-year [2] - Qiagen has outperformed consensus EPS estimates three times over the last four quarters and has topped revenue estimates four times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.56 on revenues of $505.92 million, while for the current fiscal year, the estimate is $2.27 on revenues of $2.02 billion [7] - The trend of estimate revisions for Qiagen is currently favorable, contributing to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Qiagen belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]